Daptomycin Hospira

Land: Europeiska unionen

Språk: engelska

Källa: EMA (European Medicines Agency)

Köp det nu

Bipacksedel Bipacksedel (PIL)
06-04-2022
Produktens egenskaper Produktens egenskaper (SPC)
06-04-2022

Aktiva substanser:

daptomycin

Tillgänglig från:

Pfizer Europe MA EEIG

ATC-kod:

J01XX09

INN (International namn):

daptomycin

Terapeutisk grupp:

Antibacterials for systemic use,

Terapiområde:

Soft Tissue Infections; Skin Diseases, Bacterial

Terapeutiska indikationer:

Daptomycin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus. It isrecommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB).In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, daptomycin should be co-administered with appropriate antibacterial agent(s).Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Produktsammanfattning:

Revision: 13

Bemyndigande status:

Authorised

Tillstånd datum:

2017-03-22

Bipacksedel

                                38
B. PACKAGE LEAFLET
39
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
DAPTOMYCIN HOSPIRA 350 MG POWDER FOR SOLUTION FOR INJECTION/INFUSION
daptomycin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even
if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or nurse. This
includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Daptomycin Hospira is and what it is used for
2.
What you need to know before you are given Daptomycin Hospira
3.
How Daptomycin Hospira is given
4.
Possible side effects
5.
How to store Daptomycin Hospira
6.
Contents of the pack and other information
1.
WHAT DAPTOMYCIN HOSPIRA IS AND WHAT IT IS USED FOR
The active substance in Daptomycin Hospira powder for solution for
injection/infusion is daptomycin.
Daptomycin is an antibacterial that can stop the growth of certain
bacteria. Daptomycin Hospira is used in
adults and in children and adolescents (age from 1 to 17 years) to
treat infections of the skin and the
tissues below the skin. It is also used to treat infections in the
blood when associated with skin infection.
Daptomycin Hospira is also used in adults to treat infections in the
tissues that line the inside of the heart
(including heart valves) which are caused by a type of bacteria called
_Staphylococcus aureus._
It is also
used to treat infections in the blood caused by the same type of
bacteria when associated with heart
infection.
Depending on the type of infection(s) that you have, your doctor may
also prescribe other antibacterials
while you are receiving treatment with Daptomycin Hospira.
2.
WHAT YOU NEED TO KNOW BEFORE YOU ARE GIVEN DAPTOMYCIN HOSPIRA
YOU SHOULD NOT BE GIVEN DAPTOMYCIN HOSPIRA
If 
                                
                                Läs hela dokumentet
                                
                            

Produktens egenskaper

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Daptomycin Hospira 500 mg powder for solution for injection/infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Each vial contains 350 mg daptomycin.
One mL provides 50 mg of daptomycin after reconstitution with 7 mL of
sodium chloride 9 mg/mL
(0.9%) solution for injection.
Daptomycin Hospira 500 mg powder for solution for injection/infusion
Each vial contains 500 mg daptomycin.
One mL provides 50 mg of daptomycin after reconstitution with 10 mL of
sodium chloride 9 mg/mL
(0.9%) solution for injection.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Daptomycin Hospira 350 mg powder for solution for injection/infusion
Powder for solution for injection/infusion.
A light yellow to light brown lyophilised cake or powder.
Daptomycin Hospira 500 mg powder for solution for injection/infusion
Powder for solution for injection/infusion.
A light yellow to light brown lyophilised cake or powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Daptomycin is indicated for the treatment of the following infections
(see sections 4.4 and 5.1).
-
Adult and paediatric (1 to 17 years of age) patients with complicated
skin and soft-tissue infections
(cSSTI).
-
Adult patients with right-sided infective endocarditis (RIE) due to
_Staphylococcus aureus. _
It is
recommended that the decision to use daptomycin should take into
account the antibacterial
susceptibility of the organism and should be based on expert advice
(see sections 4.4 and 5.1).
-
Adult and paediatric (1 to 17 years of age) patients with
_ Staphylococcus aureus _
bacteraemia (SAB).
In adults, use in bacteraemia should be associated with RIE or with
cSSTI, while in paediatric
patients, use in bacteraemia should be associated with cSSTI.
3
Daptomycin is active against Gram positive bacteria only (see section
5.1). In mixed infec
                                
                                Läs hela dokumentet
                                
                            

Dokument på andra språk

Bipacksedel Bipacksedel bulgariska 06-04-2022
Produktens egenskaper Produktens egenskaper bulgariska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport bulgariska 18-04-2018
Bipacksedel Bipacksedel spanska 06-04-2022
Produktens egenskaper Produktens egenskaper spanska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport spanska 18-04-2018
Bipacksedel Bipacksedel tjeckiska 06-04-2022
Produktens egenskaper Produktens egenskaper tjeckiska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport tjeckiska 18-04-2018
Bipacksedel Bipacksedel danska 06-04-2022
Produktens egenskaper Produktens egenskaper danska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport danska 18-04-2018
Bipacksedel Bipacksedel tyska 06-04-2022
Produktens egenskaper Produktens egenskaper tyska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport tyska 18-04-2018
Bipacksedel Bipacksedel estniska 06-04-2022
Produktens egenskaper Produktens egenskaper estniska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport estniska 18-04-2018
Bipacksedel Bipacksedel grekiska 06-04-2022
Produktens egenskaper Produktens egenskaper grekiska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport grekiska 18-04-2018
Bipacksedel Bipacksedel franska 06-04-2022
Produktens egenskaper Produktens egenskaper franska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport franska 18-04-2018
Bipacksedel Bipacksedel italienska 06-04-2022
Produktens egenskaper Produktens egenskaper italienska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport italienska 18-04-2018
Bipacksedel Bipacksedel lettiska 06-04-2022
Produktens egenskaper Produktens egenskaper lettiska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport lettiska 18-04-2018
Bipacksedel Bipacksedel litauiska 06-04-2022
Produktens egenskaper Produktens egenskaper litauiska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport litauiska 18-04-2018
Bipacksedel Bipacksedel ungerska 06-04-2022
Produktens egenskaper Produktens egenskaper ungerska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport ungerska 18-04-2018
Bipacksedel Bipacksedel maltesiska 06-04-2022
Produktens egenskaper Produktens egenskaper maltesiska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport maltesiska 18-04-2018
Bipacksedel Bipacksedel nederländska 06-04-2022
Produktens egenskaper Produktens egenskaper nederländska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport nederländska 18-04-2018
Bipacksedel Bipacksedel polska 06-04-2022
Produktens egenskaper Produktens egenskaper polska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport polska 18-04-2018
Bipacksedel Bipacksedel portugisiska 06-04-2022
Produktens egenskaper Produktens egenskaper portugisiska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport portugisiska 18-04-2018
Bipacksedel Bipacksedel rumänska 06-04-2022
Produktens egenskaper Produktens egenskaper rumänska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport rumänska 18-04-2018
Bipacksedel Bipacksedel slovakiska 06-04-2022
Produktens egenskaper Produktens egenskaper slovakiska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport slovakiska 18-04-2018
Bipacksedel Bipacksedel slovenska 06-04-2022
Produktens egenskaper Produktens egenskaper slovenska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport slovenska 18-04-2018
Bipacksedel Bipacksedel finska 06-04-2022
Produktens egenskaper Produktens egenskaper finska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport finska 18-04-2018
Bipacksedel Bipacksedel svenska 06-04-2022
Produktens egenskaper Produktens egenskaper svenska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport svenska 18-04-2018
Bipacksedel Bipacksedel norska 06-04-2022
Produktens egenskaper Produktens egenskaper norska 06-04-2022
Bipacksedel Bipacksedel isländska 06-04-2022
Produktens egenskaper Produktens egenskaper isländska 06-04-2022
Bipacksedel Bipacksedel kroatiska 06-04-2022
Produktens egenskaper Produktens egenskaper kroatiska 06-04-2022
Offentlig bedömningsrapport Offentlig bedömningsrapport kroatiska 18-04-2018

Sök varningar relaterade till denna produkt